Association for Research in Vision and Ophthalmology

A wave of novel gene therapies is on the horizon as treatments for patients with retinitis pigmentosa.

In the second leg of a weighty interview, Kaufman ruminates on what more is needed.

Nguyen has had the fortune of having been involved in the trials of all three.

$1 million is up for grabs

Babies exposed to marijuana in the womb may require clinical care sooner.

Cataracts are one of the most common diagnosis in eye care but there is still work being done to help treat the condition in the most effective way possible.

Yutao Liu, MD, PhD, Georgia Regents University, discussed how he and his team can potentially target genes to either reduce glaucoma or provide neuroprotection specifically for the mitochondria in the retina.

Henry Kaplan, MD, KY Lions Eye Center, University of Louisville School of Medicine, is focusing his efforts on figuring out how to preserve or recover lost central vision in patients with retinitis pigmentosa.

Neeraj Agarwal, PhD, FARVO, shared his unique perspective of marrying his prior clinical research to his current institutional landscape at the NIH.

Andrew Hartwick, PhD, The College of Optometry at The Ohio State University wants to understand why regardless of normal, standard vision tests, there is still clearly something wrong with pateints' sight.

Aflibercept exerts anti-angiogenic effects against galectin-1, a galactoside-binding lectin protein and novel angiogenic factor associated with proliferative diabetic retinopathy.

Patients with the hereditary degenerative eye disease retinitis pigmentosa (RP) may delay their loss of daytime vision by taking a traditional Chinese plant remedy Lycium barbarum also known as goji berry or wolfberry.